The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.
Melissa Brammer
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Geneviève Gauthier
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Annie Guérin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Philippe Giguere-Duval
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Eric Q. Wu
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Eduardo Santos
Employment or Leadership Position - Genentech